Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

ulation, entry criteria and study conduct. OncoGenex plans to

revise and submit the protocol to FDA for a Special Protocol

Assessment prior to initiating the registration trial.

- OncoGenex completed patient enrollment in its Phase 1 clinical trial

evaluating the safety of SN2310 in patients with advanced cancer.

Conference Call on Monday, November 10, 2008 at 4:30 p.m. Eastern Time

OncoGenex management will host a conference call on Monday, November 10, 2008, at 4:30 p.m. Eastern Time to provide a business and product update and discuss the third quarter results. To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at http://www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7903 (U.S. & Canada) or 719-325-4917 (International). A webcast replay will be available approximately two hours after the call and will be archived on http://www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... AACC, a global scientific and medical professional ... an updated brand identity today that reflects the organization,s ... healthcare environment and continue to do what they do ... the care they need. " The ... essential role in saving lives and making people healthier," ...
(Date:8/1/2014)... , Aug. 1, 2014 Research and ... "Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism ... variations of SNPs in the genome of various species. ... SNP genotyping and analysis technology can analyze thousands of ...
(Date:8/1/2014)... Aug. 1, 2014 Glencoe Software, ... of "Data InPress" ( http://glencoesoftware.com/data-inpress.html ), a ... multidimensional image data into on-line publications.  The ... Video Injection Service. Photo - ... http://photos.prnewswire.com/prnh/20140731/132409 The DataViewer ...
(Date:7/31/2014)... DENVER , July 31, 2014 Today BioSpace , ... BioMidwest Hotbed map campaign spotlighting the life sciences community in ... , Kansas , Michigan , ... Nebraska , Ohio and Wisconsin ... employment with 11 percent of all job postings on BioSpace originating in ...
Breaking Biology Technology:AACC Debuts Refreshed Brand Identity 2Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Midwest Biotech Leaders Featured On BioSpace Map 2
... for Monday, October 6, 2008 at 3:00 ... ARCA biopharma, Inc., a,biopharmaceutical company developing ... diseases, today announced that,Richard Brewer, the company,s ... Bristow, M.D., ARCA,s chairman and chief science ...
... make Zevalin only Radioimmunotherapy in U.S. to be Indicated ... for ... Therapeutics, Inc. (CTI),(Nasdaq and MTA: CTIC) announced today that it ... Food and Drug,Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) ...
... No. 40/2008, - To OMX Nordic Exchange Copenhagen ... grant of license to Roche Diagnostics for,use of the ... technology., Roche Diagnostics will develop its new product ... that is based on Exiqon,s,proprietary LNA(TM) detection technology., ...
Cached Biology Technology:ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 2ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 3ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 4ARCA biopharma to Present at JMP Securities Healthcare Focus Conference 5Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5Exiqon A/S Today Announces a Grant of License to Roche Diagnostics 2Exiqon A/S Today Announces a Grant of License to Roche Diagnostics 3
(Date:8/1/2014)... 2014 The Journal of Nutrition Education and Behavior ... Educational Material (GEM) awards, which were presented at the ... "Nutrition Education Impact: Local to Global," in Milwaukee, Wisconsin, ... awards recognize the authors of the best article and ... by members of the JNEB Journal Committee and Board ...
(Date:8/1/2014)... of a new study, including two Simon Fraser ... industry representatives and policymakers must collaborate closely on ... gas development. Viorel Popescu and Maureen Ryan, David ... Sciences department, are among eight international co-authors of ... Ecology and the Environment . , Shale gas ...
(Date:7/31/2014)... GAINESVILLE, Fla. --- By tracing nearly 3,000 genes ... moths, University of Florida scientists have created an ... to use large-scale, next-generation DNA sequencing. , ... more closely related to small moths than to ... how butterflies evolved. The study also found that ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3
... Saturday can be the worst enemy for our waistlines, according ... Louis. They found that study subjects on strict diet ... expected because they eat more on weekends than during the ... publication of the journal Obesity . Past research ...
... an alumnus and noted international business executive, has made ... effective and sustainable solutions to problems of energy and ... total $100 million, to create the Gerhard R. Andlinger ... of Engineering and Applied Science. The Andlinger ...
... according to a new study published in the American ... Fowler and Christopher T. Dawes, of the University of ... University of Southern California, is the first to show ... wide range of political activities. See the full ...
Cached Biology News:Weekends slow weight loss, researchers find 2Weekends slow weight loss, researchers find 3Gift of $100 million to transform energy and environment research at Princeton 2Gift of $100 million to transform energy and environment research at Princeton 3Gift of $100 million to transform energy and environment research at Princeton 4Political participation is partially rooted in genetic inheritance 2Political participation is partially rooted in genetic inheritance 3
... gene gun low-pressure system, 100-120 V, is ... into cells. The system includes the Helios ... tubing prep station, syringe kit, tubing cutter, ... and instructions. The dimensions of the gene ...
... optimization kit is for fine-tuning the bombardment ... kit is recommended when you are first ... kit includes 0.25 g each of 0.6 ... gold microcarriers, 100 each of 9 rupture ...
... Blocker Arrays can be used to ... various proteins and sera that are commonly ... The array contains spots for 21 different ... Determination of antibody crossreactivity and species specificity, ...
... microplate coating using advanced automated high throughput microplate processing equipment ... can also accommodate virtually any lot size of the following ... 8 and 12 well strips, ... 384 well microplate, ...
Biology Products: